Introduction {#s1}
============

Malaria is an important parasitic disease that causes a high level of mortality worldwide. In 2018, malaria was estimated to have caused 405,000 deaths, most of them attributable to the virulent *Plasmodium falciparum* parasite species ([@bib62]). Most malaria cases occur in Sub-Saharan Africa, but Southeast Asia and South America are also affected. Since 2001, Artemisinin-based Combination Therapies (ACTs) have been the recommended first-line therapy for *P. falciparum* infection for almost all malaria-endemic areas ([@bib59]). ACTs combine an artemisinin derivative and one partner drug (most commonly lumefantrine, mefloquine, amodiaquine, piperaquine or pyronaridine). These treatments have contributed to a major reduction in malaria-related mortality and morbidity ([@bib20]; [@bib9]; [@bib7]). However, in 2008, the first instances of reduced artemisinin efficacy were described in western Cambodia ([@bib17]; [@bib5]). Subsequent studies have documented the rapid spread of resistance throughout Southeast Asia ([@bib17]; [@bib5]; [@bib61]). Resistance to artemisinin is partial and affects only rings ([@bib61]). Clinically, this partial resistance trait manifests as a parasite clearance half-life that exceeds 5.5 hr ([@bib63]). This half-life represents the time required to achieve a two-fold reduction of the parasite biomass. Partial resistance also manifests as persistent parasitemia on day three with a complete clearance of parasites following full treatment with an artesunate monotherapy lasting seven days or with an ACT ([@bib61]). An analysis of *P. falciparum* parasites selected for artemisinin resistance *in vitro* as well as parasites from patients experiencing slow parasite clearance led to the identification of a genetic locus linked to resistance: a kelch domain-containing protein located on chromosome 13 (*pfk13*) ([@bib4]). To date, many missense mutations have been described in the BTP/POZ or kelch propeller domain-containing parts of this protein in clinical isolates, however only nine of them have been validated for artemisinin resistance (F446I, N458Y, M476I, Y493H, R539T, I543T, P553L, R561H and C580Y) ([@bib61]; [@bib4]; [@bib51]). A larger number have been associated with delayed parasite clearance ([@bib63]). In most locations, the *pfk13* C580Y mutation has overtaken other resistance-inducing variants, and it is now the most prevalent *pfk13* variant in Southeast Asia ([@bib5]; [@bib4]).

South America has historically been a second hotspot outside Southeast Asia for the evolution of antimalarial drug resistance. For example, chloroquine and sulfadoxine-pyrimethamine resistance evolved simultaneously in both regions ([@bib58]; [@bib46]). The Guiana Shield region of South America, which includes Guyana, Suriname, French Guiana and parts of Brazil, Venezuela and Colombia, is important as a potential source of emerging antimalarial drug resistance. In this region, the subsoil is rich in gold and other minerals, leading to extensive mining activities in forested areas. These mining activities favor malaria transmission, particularly *P. falciparum* ([@bib18]; [@bib26]). Mining also generates human population movement and inappropriate use of ACTs, as people generally work deep in the forest, far from medical care ([@bib43]; [@bib19]). This erratic use of ACTs, as well as self-medication using ACTs of substandard quality or artemisinin monotherapies, may promote the emergence of resistance to artemisinin.

In Guyana in 2010, 5.1% (5 out of 98) of *P. falciparum*-infected clinical samples, sharing a common haplotype different from their Cambodian counterparts, exhibited the *pfk13* C580Y mutation ([@bib13]). However, no clinical or *in vitro* resistance phenotypes were measured or associated with the genotype data. The most recent therapeutic efficacy study conducted in Guyana in 2014 with 50 patients failed to identify *pfk13* mutations or delayed parasite clearance time after artemether/lumefantrine treatment ([@bib45]). The sample size, however, was too small to ensure detection of low-frequency resistance mutations. The objective of the present study was to evaluate whether *pfk13* variants (C580Y or others) have persisted in Guyana since 2010, and if so, to evaluate their prevalence in 2016--2017. In the absence of available clinical phenotypes associated with the *pfk13* C580Y variant from patients infected and treated in this region, we evaluated the impact of two *pfk13* mutations, C580Y and R539T, on *in vitro* resistance and the rate of parasite growth in a South American parasite genetic background.

Results {#s2}
=======

Recent circulation of the *pfk13* C580Y mutation on a single clonal background {#s2-1}
------------------------------------------------------------------------------

We genotyped the propeller domain of the *pfk13* gene by Sanger sequencing 854 samples collected between March 2016 and September 2017 from different malaria-endemic regions of Guyana. Fourteen samples bearing the *pfk13* C580Y variant were identified, representing a prevalence of 1.6% (CI~95~0.8--2.5%). The prevalence of mutants was 8.8% (CI~95~3.6--14.0%) in Region 1, 0.7% (CI~95~0.0--2.0%) in Region 8 and 0.5% (CI~95~0.0--1.1%) in Region 7 ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). We also genotyped the sequence outside of the propeller domain for 283 samples. Among these, 57.2% (CI~95~51.5--63.0%) were the 3D7 reference genotype, 42.0% (CI~95~36.3--47.8%) carried the *pfk13* K189T mutation and 0.7% (CI~95~0.0--1.7%) had a mixed genotype (wild-type/K189T). All samples bearing the *pfk13* C580Y variant also exhibited the *pfk13* K189T mutation, which to date has not been associated with artemisinin resistance.

![Distribution of the *pfk13* C580Y mutant parasites among Guyana regions.\
Pie charts represent the total number of isolates analyzed per region. Mutants are represented in red.\
Figure 1---source data 1.Number of clinical samples with *pfk13* propeller segment WT or C580Y mutant, analyzed by sampling regions in Guyana from March 2016 to September 2017.](elife-51015-fig1){#fig1}

To understand the origin of the C580Y mutation and examine the genetic relatedness of the mutant strains, we performed whole-genome sequencing (WGS) on thirteen of the fourteen Guyana samples exhibiting the *pfk13* C580Y mutation, as well as 40 comparator samples exhibiting wild-type *pfk13* and collected at comparable locations and times. The variant profile observed in the sequenced samples identified that the *pfk13* C580Y variant arose on a single Guyanese parasite genetic background, and was not imported from Southeast Asia ([Figure 2a](#fig2){ref-type="fig"}). Deeper examination of the genomic similarity was performed by estimating the proportion of the genome that was identical-by-descent between sample pairs. This analysis revealed an extremely high level of relatedness between sample pairs bearing *pfk13* C580Y (identity by descent (IBD) \>0.77) relative to pairwise comparisons containing at least one wild-type *pfk13* sample ([Figure 2b](#fig2){ref-type="fig"}). This indicates that the parasite lineage on which C580Y arose in Guyana in 2010 probably engaged in limited sexual outcrossing with other parasite lineages in Guyana, despite having persisted for a sufficient duration of time to be observed in multiple regions of the country and to have risen to a non-negligible frequency in the Region 1 population.

![Whole-genome sequence analysis of *pfk13* C580Y mutant parasites in Guyana.\
(**a**) Comparison of the haplotypic background of *pfk13* C580Y mutant parasites from Guyana, 2016, and Southeast Asia, 2010--2012. Across Pf3k samples from Cambodia, Thailand, and Vietnam, 45 unique C580Y-coding haplotypic backgrounds were identified and compared to haplotypes from Guyana. Columns represent 149 sites containing non-singleton single nucleotide polymorphisms (SNPs) found within a 150 kb segment surrounding the *pfk13* C580Y-coding allele. At a given site, the more common allele is marked blue, the less common allele is orange, and missing calls are grey. The Y-coding variant for codon 580 of *pfk13* is represented by the red blocks; wild-type is blue. Only the five *pfk13* C580Y mutant samples with fewer than 15% missing calls are depicted here. (**b**) Analysis of relatedness at the whole-genome level among Guyana clones. Pairwise identity-by-descent (IBD) was estimated for all pairs of Guyana samples with high quality whole-genome sequence data (\<70% missing calls). Pairwise comparisons between samples exhibiting the *pfk13* C580Y allele are indicated in red, and show uniformly high levels of relatedness, suggesting a single clonal lineage harboring the resistance mutation. (**c, d**) Principal components analysis of parasites from Guyana or other geographic regions using SNP calls from whole-genome sequence data. (**c**) The parasites from Guyana and French Guiana form a single cluster when compared with parasites from Africa. (**d**) The two edited parasite lines from French Guiana are highly similar to the sequenced parasite samples from Guyana including a *pfk13* mutant.](elife-51015-fig2){#fig2}

In the 75 kb segments flanking the 2016--2017 C580Y-coding variant, WGS identified only two low-quality single nucleotide variants among the 13 mutant samples ([Figure 2a](#fig2){ref-type="fig"}). We also analyzed *pfk13* C580Y parasites using eight microsatellite loci flanking the *pfk13* gene. Despite missing data for some loci in some samples, two different haplotypes were identified, differing at one locus positioned at −6.36 kb ([Table 1](#table1){ref-type="table"}). The previously identified Guyana A mutant haplotype ([@bib13]) matched the most common haplotype in the 2016--2017 samples, which was markedly distinct from the one observed in *pfk13* Cambodian mutants ([@bib13]). The second 2016 haplotype exhibiting the 280 allele at the locus −6.36 kb has not been previously identified. As replicate genotyping efforts reproduced the allelic variant at locus −6.36, it is likely that a *de novo* microsatellite mutation occurred at locus −6.36 following the origin of the C580Y mutation. The high similarity of the microsatellite haplotypes bearing C580Y between 2010 ([@bib13]) and 2016 suggests that the chromosome 13 resistance haplotype, and perhaps the full clonal lineage, has persisted over this timespan, as several of the allelic markers associated with the C580Y mutation are rare in both studies (*e.g.* allele 277 at marker −6.36: 11%; allele 206 at marker −0.15: 9%; allele 244 at marker 72.3: 6% [@bib13]). We were not able to procure remaining DNA from the samples collected in 2010 to determine whether the entire genomic background has been preserved intact as a clonal lineage between 2010 and 2016. However, the genotypes of the molecular markers for resistance (*pfcrt*, *pfdhps*, *pfdhfr* and *pfmdr1*) were also similar between 2010 and 2016 mutant samples ([Supplementary file 1](#supp1){ref-type="supplementary-material"}).

###### *pfk13* microsatellite analysis of Guyanese and Cambodian isolates.

  Name         Region    Year of collection   −31.9   −6.36   −3.74   −0.15   K13°    3.4   8.6   15.1   72.3
  ------------ --------- -------------------- ------- ------- ------- ------- ------- ----- ----- ------ ------
  T145         1         2016                 203     277     170     206     C580Y   138   262   144    244
  T237         7         2016                 203     277     170     206     C580Y   138   262   144    244
  T244         1         2016                 203     280     170     NA      C580Y   138   NA    144    NA
  T305         1         2016                 203     277     170     206     C580Y   138   262   144    244
  T345         1         2016                 203     277     170     206     C580Y   138   262   144    244
  T364         1         2016                 203     277     170     206     C580Y   138   262   144    244
  T378         1         2016                 203     277     170     206     C580Y   NA    262   144    244
  T385         7         2016                 203     277     170     206     C580Y   138   262   144    244
  T445         1         2016                 203     277     170     206     C580Y   NA    262   144    244
  T490         7         2016                 203     280     170     206     C580Y   NA    262   144    244
  T508         8         2016                 203     277     170     206     C580Y   138   262   144    244
  T314         1         2016                 NA      NA      NA      NA      C580Y   NA    NA    NA     NA
  T649         1         2016                 NA      NA      NA      NA      C580Y   NA    NA    NA     NA
  GUY0183      1         2017                 ND      ND      ND      ND      C580Y   ND    ND    ND     ND
  T208         7         2016                 203     280     152     192     WT      138   284   138    244
  T265         7         2016                 203     280     156     192     WT      102   262   144    238
  T317         1         2016                 NA      NA      156     190     WT      NA    262   144    244
  T332         7         2016                 NA      NA      154     190     WT      102   262   144    244
  T504         8         2016                 203     280     152     192     WT      138   284   138    244
  T524         7         2016                 NA      NA      170     192     WT      102   270   NA     NA
  T634         8         2016                 205     280     156     192     WT      102   262   144    238
  T724         8         2016                 203     280     154     192     WT      NA    284   138    240
                                                                                                         
  Guyana A\*   1 and 7   2010                 203     277     170     206     C580Y   138   262   144    244
  Guyana B\*   7         2010                 203     277     170     206     C580Y   138   262   144    240
                                                                                                         
  MRA 1236\*             2010                 201     283     146     194     C580Y   130   286   138    NA
  MRA 1240\*             2011                 201     283     146     194     R539T   122   264   138    244
  MRA 1241\*             2011                 201     283     146     194     I453T   130   290   138    244
                                                                                                         
  3D7                                         207     283     164     226     WT      160   274   147    242
  7G8                                         225     280     158     196     WT      102   262   144    240

°Codons 438--704, NA: No Amplification, ND: Not Done, \*: Mutants from [@bib13] according to the new size-assignment for microsatellites.

Evidence for a Guyana-specific genetic background of *pfk13* C580Y mutants {#s2-2}
--------------------------------------------------------------------------

The observation of the C580Y mutation persisting in only one clonal lineage suggests that genomic background may be an important determinant of the emergence and persistence of *pfk13* propeller mutations in Guyana, as was previously observed in Southeast Asia ([@bib38]; [@bib39]; [@bib10]; [@bib2]). We therefore compared the genetic background of 53 isolates from Guyana (40 *pfk13* wild-type and 13 *pfk13* C580Y) and the artemisinin-resistant background observed in Southeast Asian parasites, in order to explore whether partner mutations associated with *pfk13*-mutant parasites may be responsible for the preservation of this clonal lineage ([@bib39]). None of the previously described mutations were observed, including the *pffd* D193Y, *pfcrt* N326S, *pfcrt* I356T, *pfarps* V127M and *pfmdr2* T484I variants. The *pfcrt* gene was of South American origin with a 7G8 haplotype comprising the mutations C72S, K76T, A220S, N326D and I356L, with no particular difference between wild-type and *pfk13* C580Y parasites ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). However, within this candidate gene set, we observed two fixed differences between wild-type and *pfk13* C580Y parasites, both within the gene *PF3D7_1252100* (*RON3*) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Although overall genotyping rates were low in this gene (successful for 15 out of 53), all genotyped *pfk13* C580Y mutants (n = 5) contained a V1661L-coding variant and all genotyped *pfk13* wild-type parasites (n = 9) carried a synonymous non-reference variant at codon 1801. We also analyzed other molecular markers for resistance (*pfcrt*, *pfdhps*, *pfdhfr* and *pfmdr1*) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). All *pfk13* C580Y variants were *pfcrt* SVMNT (72-76)/A220S/N326D/C350/I356L (i.e. the *pfcrt* 7G8 haplotype), *pfdhfr* double-mutant (N51I/S108N), *pfdhps* triple-mutant (A437G/K540E/A581G) and *pfmdr1* triple-mutant (Y184F/N1042D/D1246Y). In summary, Guyanese parasites bearing *pfk13* C580Y also exhibited variants in genes previously associated with separate antimalarial drug resistance phenotypes in Southeast Asia.

A single *pfk13* C580Y clone has fluctuated through time without massive spreading {#s2-3}
----------------------------------------------------------------------------------

The highest prevalence of the Guyanese *pfk13* C580Y variant was found in Region 1. This variant was first observed in April 2016 and achieved a maximum prevalence of 25.0% (CI~95~3.8--46.2%) in June 2016 ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Thereafter, it was not identified between September 2016 and March 2017 despite a constant transmission level of malaria in this region during this period. To understand these fluctuations in prevalence, we studied the parasite population dynamics in the country. We compared parasites from Guyana to samples from Africa and Southeast Asia ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). At synonymous sites within 4888 genes, pairwise nucleotide diversity (π~syn~) in Guyana was 3.4 × 10^−4^, less than half the level observed in Southeast Asia (7.4 × 10^−4^) and nearly a third of that measured in Africa (1.0 × 10^−3^). In Guyana, 46 samples had sufficient sequencing coverage to assess their complexity of infection (COI), and only one (2.2%) showed evidence of multiple parasite lineages (COI \> 1). In contrast, multiclonal infection estimates from Africa and Southeast Asia are routinely higher ([@bib11]; [@bib23]; [@bib6]; [@bib65]). Despite the low nucleotide diversity and small proportion of multiclonal infections, Guyana harbors a relatively high number of distinct parasite lineages and few parasite pairs with identical genomes. We found that only 0.54% of wild-type Guyanese parasite pairs showed evidence of belonging to the same clonal lineage (IBD \>0.75).

![Temporal distribution of *pfk13* C580Y mutants in Region 1 of Guyana per month of collection, 2016--2017.\
The percentage of *pfk13* C580Y mutants for each month of identification is represented above each bar.\
Figure 3---source data 1.Number of clinical samples with *pfk13* WT or C580Y mutant alleles in Region 1 of Guyana from March 2016 to September 2017.](elife-51015-fig3){#fig3}

*pfk13* C580Y and R539T mutations generate *in vitro* artemisinin resistance in cultured parasites from the Amazonia {#s2-4}
--------------------------------------------------------------------------------------------------------------------

To evaluate the impact of the *pfk13* C580Y mutation on artemisinin susceptibility in parasites, we culture-adapted two *P. falciparum* isolates (O141-A and R086) from French Guiana (a neighboring country in the Guiana Shield) and genetically edited these lines using a previously described zinc-finger nuclease (ZFN) based approach ([@bib51]). We also evaluated the impact of the variant arginine to threonine mutation at codon 539 (R539T), associated with one of the highest *in vitro* artemisinin resistance levels in Asian parasites ([@bib4]; [@bib51]). These two culture-adapted lines both exhibit the *pfcrt* SVMNT haplotype that is associated with chloroquine resistance, but only R086 carries the *pfcrt* C350R mutation that was earlier found to restore chloroquine susceptibility to South American parasites despite the presence of the SVMNT haplotype ([@bib42]). These parasite lines from French Guiana exhibit a high level of genomic similarity to our genome-sequenced Guyanese parasites ([Figures 2c and d](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). These findings suggest that phenotypes observed in these lines from French Guiana are relevant for understanding the impact of the *pfk13* C580Y variant in Guyanese parasites, none of which have yet been adapted to *in vitro* culture.

We produced isogenic lines expressing the wild-type *pfk13* allele (R086^ctrl^, O141-A^ctrl^) or the *pfk13* C580Y mutation (R086^C580Y^, O141-A^C580Y^), or the *pfk13* R539T allele in the case of R086 (R086^R539T^). We measured the phenotypic impact of those mutations on *in vitro* artemisinin resistance in edited and parental lines using the Ring-stage Survival Assay ([@bib57]) that begins with 0--3 hr post-invasion rings (RSA~0-3h~). Introducing the *pfk13* C580Y mutation caused a significant increase in the survival rate (twenty-three fold in R086: 0.6% ± 0.2 for R086 to 13.7% ± 1.5 for R086^C580Y^, p=0.006; fifty-five fold in O141-A: 0.5% ± 0.1 for O141-A compared to 27.6% ± 7.0 for O141-A^C580Y^, p=0.030, [Figure 4](#fig4){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). R086^R539T^ showed a survival rate fifty-five times higher than the parental line (33.0% ± 5.0 compared to 0.6% ± 0.2, p=0.011). Control assays found no significant difference in the survival rate of the parental *vs.* isogenic control lines (0.6% ± 0.2 for R086, 0.6% ± 0.4 for R086^ctrl^*p*=0.968, 0.5% ± 0.1 for O141-A and O141-A^ctrl^*p* = 0.899) ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}).

![Ring-stage Survival Assays in parasites from French Guiana.\
Data show survival rates of ring-stage parasites (0--3 hr post invasion of human erythrocytes) after a 6 hr pulse of 700 nM DHA, as measured by microscopy 66 hr later. Data illustrate mean ± SEM percent survival from three independent repeats compared with dimethyl sulfoxide (DMSO)-treated parasites as a control for two isolates from French Guiana (O141-A, R086). Parents harbored wild-type *pfk13* allele, and for zinc-finger nuclease edited isogenic parasites, control (ctrl) isolates harbored wild-type *pfk13* allele with silent mutations or *pfk13* mutations (C580Y or R539T). IPC4912, a Cambodian reference strain harboring the I543T *pfk13* mutation was used as a control. A parasite line is considered resistant when the survival rate is greater than 1%. Student's t-test was used to assess significant differences between survival rates of parental and *pfk13*-edited parasites. \*p\<0.05; \*\*p\<0.01; ns: not significant.\
Figure 4---source data 1.Survival rates obtained on *pfk13* gene-edited (wild-type, C580Y or R539T) isogenic field isolates from French Guiana.](elife-51015-fig4){#fig4}

*Pfk13* C580Y and R539T have a fitness impact on parasites depending on the genetic background {#s2-5}
----------------------------------------------------------------------------------------------

To assess the *in vitro* fitness of the *pfk13* mutants relative to the wild-type isogenic lines, we performed a competitive growth assay by co-culturing each pair of mutant and wild-type isogenic parasite lines and measuring the *pfk13* allele frequencies over 60 days (\~30 asexual generations). This was achieved using a highly sensitive and robust Taqman allelic discrimination real-time PCR (qPCR) assay ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}, [Figure 5---figure supplement 1---source data 1](#fig5s1sdata1){ref-type="supplementary-material"}, [Figure 5---figure supplement 2---source data 1](#fig5s2sdata1){ref-type="supplementary-material"}) that was able to accurately quantify the different proportions of the mutant alleles in these samples. Results showed a modest growth deficit in *pfk13* mutants compared to the wild-type parent for both the R086 and O141-A lines, suggesting that the *pfk13* C580Y and R539T mutations negatively impact parasite growth. Over the 60 day period, we observed an 18% reduction in the frequency of the R539T mutant for the R086 line, and larger significant reductions of 24% and 40% in allele frequencies of the C580Y mutants of R086 and O141-A compared to their respective isogenic wild-type counterparts ([Figure 5a](#fig5){ref-type="fig"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). This reflected an average reduced growth rate of −0.6%, −0.8% and −1.3% per 48 hr generation of the R086^R539T^, R086^C580Y^ and O141-A^C580Y^ mutant lines, respectively, across 30 generations ([Figure 5b](#fig5){ref-type="fig"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). In addition to observing that the C580Y mutation conferred a higher fitness cost compared to the R539T mutation, we also saw that the parasite genetic background contributed to the severity of the fitness deficit, as the growth defect in the C580Y mutation was substantially more pronounced in O141-A compared with R086 parasites ([Figure 5](#fig5){ref-type="fig"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}).

![Competition growth assays of *pfk13* mutant and wild-type parasites.\
(**a**) Frequency of wild-type and mutant parasites in co-culture, as measured by TaqMan allelic discrimination qPCR. Data show the percentage of *pfk13* mutant parasites in the culture over 60 days with sampling every two days. Error bars represent the SEM of *pfk13* mutant allele frequency between the two biological replicates (including two technical replicates for qPCR). A percentage below 50% indicates the mutant was less fit than the isogenic *pfk13* wild-type line. (**b**) Percentage change per generation of *pfk13* mutant allele frequency relative to wild-type. Data show that *pfk13* mutations confer an *in vitro* fitness cost in both parasite lines. Differences in growth rates were calculated as the percent change in *pfk13* mutant allele frequency averaged over 30 generations. Error bars represent the SEM of percentage growth change between the two biological sampling experiments calculated for every generation in each co-culture. Significance was calculated using the Wilcoxon signed-rank test in every generation across the two biological replicate experiments. \*\*p\<0.01, \*\*\*p\<0.001; ns: not significant.\
Figure 5---source data 1.Proportion of *pfk13* mutants compared to *pfk13* wild-type during 60 days of *in vitro* co-culture.](elife-51015-fig5){#fig5}

Discussion {#s3}
==========

Results presented herein confirm the *de novo* emergence and long-term persistence of the *pfk13* C580Y artemisinin resistance mutation in Guyana, South America. Six years after their first identification, *pfk13* C580Y mutant parasites continue to circulate in Guyana at low prevalence (1.6%; 14/854). Parasites bearing this mutation belong to a single clonal lineage and are of autochthonous origin. Gene editing studies on French Guianan parasites, closely related to parasites from Guyana, showed that the *pfk13* C580Y mutation is able to mediate artemisinin resistance *in vitro* at levels observed in Southeast Asian parasites harboring this mutation. An adverse impact of this *pfk13* mutation on asexual blood stage growth rates of *pfk13-*edited French Guianan parasite lines in culture was also observed, providing evidence of a fitness cost similar to that previously described for Southeast Asian lines ([@bib40]; [@bib32]).

During the 1990s, analyses of resistant parasites retrospectively suggested the simultaneous emergence of resistance to chloroquine and sulfadoxine/pyrimethamine in parasites from Southeast Asia and the Amazonian region of South America ([@bib58]; [@bib46]; [@bib56]). With artemisinin, the same scenario is occurring with evidence of an independent emergence of resistance mutation in South America. For artemisinin resistance, there is an opportunity to dissect the first steps of resistance selection in South America in 'real time', relying on genetic markers and phenotypic assays (genotypic surveys, therapeutic efficacy studies, and *in vitro* phenotyping through the Ring-stage Survival Assay (RSA~0-3h~)) developed in Southeast Asia ([@bib4]; [@bib57]). These genetic and phenotypic tools can help address the critical questions of why *in vitro* resistance to artemisinin has emerged in Region 1 in Guyana, a country with fewer than 20,000 malaria cases in 2018, and why this resistance is not increasing more quickly. In 2004, Guyana was one of the first South American malaria-endemic countries to adopt and implement artemether-lumefantrine (Coartem), the current first-line therapy against *P. falciparum*. Six years later, in 2010, *pfk13* C580Y mutants were first identified. Until now, no further signals of artemisinin resistance or *pfk13* mutations had been identified, despite studies incorporating *pfk13* genotyping in Guyana (n = 50), Suriname (n = 40) and French Guiana (n = 198) ([@bib45]; [@bib34]; [@bib14]). Other than *pfk13* C580Y, no other *pfk13* propeller domain mutations have been observed in Guyana. In Southeast Asia, two molecular epidemiological profiles are currently observed. In Western Cambodia, one C580Y linage (KEL1) has displaced other mutations and has rapidly become the dominant *pfk13* genotype in that population (\>80%) ([@bib2]; [@bib53]). This lineage has merged with a multicopy *plasmepsin 2* and *3* lineage (PLA1) that is associated with piperaquine resistance ([@bib2]). Nowadays, this co-lineage has colonized northeastern Thailand and southern Laos ([@bib27]). On the other side, in western Thailand, at the border with Myanmar, a six-year period was required for distinct mutant *pfk13* parasite lineages to collectively reach a population prevalence of 20% ([@bib2]; [@bib3]). At the present time, a patchwork of *pfk13* genotypes co-circulates in that population and the prevalence of C580Y lineages fluctuates around 20--30% ([@bib29]). In Myanmar, *pfk13* mutants are more diverse and the F446I mutation presently dominates the *pfk13* mutant parasite population in certain sites, with this mutation being associated with an intermediate resistance phenotype ([@bib25]; [@bib8]).

Given this history of *pfk13* propeller domain mutations in Southeast Asia, beginning with a soft sweep and transitioning to a hard sweep, we might have expected an increase in the prevalence of *pfk13* C580Y mutant parasites during this 2010-2016/2017 period in Guyana. However, the situation in this part of the world differs from Southeast Asia. First, efforts to monitor *pfk13* mutations in Guyana were not systematically conducted between 2010 and 2017. Sample size could therefore explain why the C580Y mutation was only sporadically observed. Nonetheless, the present study indicates that the mutation has not drastically increased in the parasite population. Differences in the resistance profile to artemisinin partner drugs could also account for the heterogeneity in *pfk13* mutational trajectories in Southeast Asia vs. Guyana, a region where markers of resistance have historically reached fixation ([@bib42]; [@bib30]). In Southeast Asia, the rapid spread of artemisinin-resistant genomic lineages can be explained in part by a multidrug-resistant profile, which includes *pfk13* variants as well as mutations conferring resistance to the partner drug piperaquine ([@bib2]; [@bib47]; [@bib28]). Our genomic analysis of a panel of Guyanese isolates identified the common South American profile for known drug resistance markers (*pfcrt*, *pfdhps*, *pfdhfr* and *pfmdr1*) in both mutant and wild-type *pfk13* samples ([@bib58]; [@bib46]; [@bib56]; [@bib30]). In the Guiana Shield, lumefantrine remains a highly effective partner drug for artemisinin, and no mutations or phenotypes associated with lumefantrine resistance have been observed ([@bib30]). High efficacy of the partner drug could therefore be an important factor limiting the spread of *pfk13* C580Y in Guyana. Finally, both the low synonymous pairwise genetic diversity (π~syn~ = 3.4 x 10^−4^) and the low complexity of infection (COI, 2.2% of samples with a COI \> 1) in Guyana are in keeping with the expectation that the *P. falciparum* population in South America is smaller and more recently established than in Southeast Asia ([@bib64]).

The genomic structure of the Guyana parasite population could also help explain why the mutation arose there, rather than other settings in South America. The present findings indicate high outcrossing rates and few clonal lineages in Guyana (0.54% pairs with IBD \>0.75). This clonal diversity is relatively high, especially within a South American context. Previous studies have found much higher proportions of non-unique haplotype backgrounds (\>30% of samples) within parasite populations from Colombia ([@bib21]), Peru ([@bib16]), and Ecuador ([@bib48]; [@bib49]). These prior analyses used fewer genomic markers, but the results still suggest that clonal diversity may be greater in the Guiana Shield relative to the rest of the continent, possibly driven by the high *P. falciparum* transmission level observed in mining areas ([@bib18]; [@bib37]). As genomic background likely plays a key role in the persistence of resistance mutations like C580Y, this haplotype richness may increase the likelihood that resistance mutations can successfully establish themselves in a permissive background. Subsequently, a low recombination rate may allow these beneficial combinations to then persist within the population. A more definitive exploration of this hypothesis, and of whether Guyana's current clonal structure represents recent demographic change or historic population subdivision, will be possible as more whole-genome sequence data become available for the continent. The slower trajectory of *pfk13* C580Y may also be due to an impaired asexual blood-stage growth rate, and the absence of compensatory mutations that have been hypothesized to aid the spread of the C580Y mutation in Southeast Asia ([@bib2]; [@bib32]).

We chose to introduce two *pfk13* mutations by gene editing: C580Y mutation because of its presence in Guyana and its dominance in Southeast Asia, and R539T as a positive control for *in vitro* resistance, as it exhibits the highest RSA observed in Southeast Asian strains along with I543T ([@bib4]; [@bib51]). Introducing these mutations conferred high levels of *in vitro* artemisinin resistance and both mutations negatively impacted growth rates *in vitro* in our parasite isolates from French Guiana, a neighboring country of Guyana. These growth rate differences provide a surrogate marker of fitness and do not necessarily predict *in vivo* success of the mutations, as multiple other parameters are also important including gametocyte production, impacts on transmission, and immunity. Our data show that the C580Y mutation was associated with a more severe growth defect compared to the R539T mutation in these asexual blood stage parasites. A similar finding was also recently reported in C580Y-edited isolates from the Thailand-Myanmar border ([@bib40]), although disparate results were obtained for C580Y-edited isolates from Cambodia ([@bib52]). These contrasting data underline the influence of the parasite's genomic background, which potentially involves compensatory mutations that impact the overall growth. Further studies will be needed to screen for potential secondary mutations that may be offsetting these fitness costs. It will also be important to examine factors that could drive the persistence of mutant *pfk13* in Guyana despite the apparent fitness cost, including a consideration of local antimalarial drug usage and quality, transmission levels, and population movement.

The World Health Organization (WHO) has categorized countries regarding artemisinin resistance based on *pfk13* mutant prevalence and the clinical response to artemisinin derivatives ([@bib60]). The threshold of 5% of *pfk13* mutants has been met on several occasions in Guyana, first in 2010 ([@bib13]), then punctually in 2016--2017 in Region 1. The situation is evolving and a marker could disappear for reasons that are currently unclear. Nonetheless, in light of these findings, Guyana has the status of suspected resistance to artemisinin derivatives ([@bib60]). The clinical and public health significance of the presence of these mutations on the therapeutic efficacy of artemisinin-based combination therapies in Guyana, and more precisely artemether/lumefantrine - first line in the country, should be directly evaluated. We note that our study had limitations including the small number of analyzed samples and the *in vitro* phenotypic impact evaluated in parasites from nearby French Guiana and not Guyana itself. Nonetheless, we observed that *pfk13* mutants still circulated in 2016--2017. Given their decreased susceptibility to DHA *in vitro*, these mutants are likely to expose the partner drug to the risk of emerging resistance. This situation could defeat *P. falciparum* elimination strategies in this region. Therefore, national health authorities should continue to work together in order to overcome difficulties coming from their multiplicity of regulations, malaria control strategies and transmission levels in the context of major human migrations across borders. The Guiana Shield initiative launched by the Pan American Health Organization (PAHO) and the WHO in 2016 will have a crucial role to reinforce and to coordinate the different malaria control measures.

Materials and methods {#s4}
=====================

Sample collection {#s4-1}
-----------------

In collaboration with PAHO, 854 *P. falciparum* isolates were collected in Guyana from March 2016 to September 2017 in febrile individuals visiting the malaria clinic. Parasites associated with these samples came mainly from Region 1 (n = 114), 7 (n = 572) and 8 (n = 150) ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Those are the three main endemic regions for malaria in the country. Sample collection was done in patients who provided informed consent. As part of molecular surveillance established in the country, consent from the patients was not required and filter papers were collected at the diagnosis time in different clinics and hospital of the country.

DNA extraction and *pfk13* genotyping {#s4-2}
-------------------------------------

DNA was extracted from dried blood spots using the QIAmp DNA mini kit according to the manufacturer's protocol (Qiagen, Germany). The *pfk13* gene of each sample was amplified by nested PCR using published primers ([@bib4]; [@bib35]). For the primary PCR, 1 µl of DNA was amplified in a Mastermix containing: 1X of HOT FIREPol Blend Master Mix Ready to Load (12.5 mM MgCl~2~, Solis BioDyne), 3.5 mM MgCl~2~, and 0.2 µM of each primer to a final volume of 25 µl. The amplification program was: 15 min at 95°C, then 35 cycles of 30 s at 95°C, 2 min at 60°C, 2 min at 72°C, and a final extension of 10 min at 72°C. For the nested PCR, 1 µl of primary PCR product was amplified under the same conditions with the following program: 15 min at 95°C, then 40 cycles of 30 s at 95°C, 1 min at 60°C, 1 min at 72°C, and a final extension of 10 min at 72°C. Nested PCR products were detected using 2% agarose gel electrophoresis and ethidium bromide staining. Double-strand sequencing was performed by Eurofins (France). Sequences were aligned with Geneious v8.1.7 using the 3D7 *pfk13* sequence as a reference. Mutant isolates were analyzed twice to confirm results.

*pfk13*-flanking microsatellite analysis {#s4-3}
----------------------------------------

The analysis of eight microsatellite loci located upstream (−31.9,--6.36, −3.74,--0.15 kb) and downstream (3.4, 8.6, 15.1, 72.3 kb) of the *pfk13* gene within isolates from Guyana was performed as previously described ([@bib13]; [@bib12]; [@bib54]).

Genetic modification of parasites at the positions 580 and 539 of the *pfk13* gene {#s4-4}
----------------------------------------------------------------------------------

Parasites were cultured in human red blood cells in enriched RPMI medium containing 10% human serum and were propagated at 37°C in 10% O~2~, 5% CO~2~ and 85% N~2~. The enriched medium is composed of RPMI-1640 (ref 4130, Sigma Aldrich) with HEPES \[25 mM\], L-glutamine \[5 mM\], glucose \[22 mM\], NaHCO~3~5% \[25 mM\], gentamycin \[20 mM\], hypoxanthine \[0.37 mM\] and orotic acid \[1.6 µM\]. Two *P. falciparum* isolates collected in French Guiana in 2011 (O141-A) and 2014 (R086) were genetically modified using the ZFN method as previously described ([@bib51]). Briefly, donor plasmids (pZFN-K13-18/20-hDHFR-bsmut carrying the wild-type *pfk13* allele and pZFN-K13-18/20-hDHFR-**C580Y** and pZFN-K13-18/20-hDHFR-**R539T** carrying the mutated *pfk13* allele) were purified from XL10-Gold bacteria using the QIAGEN plasmid Maxi kit (ref12162) and resuspended in Cytomix. Parasites were electroporated with 50 µg of donor plasmid using the Biorad Gene-PulserII electroporator with settings of 0.31 kV and 950 µF ([@bib22]). The day after electroporation and for 6 days, parasites were exposed to 2.5 nM WR99210 (a gift from Jacobus Pharmaceuticals, Princeton, NJ). Between 20--35 days after electroporation, parasites were detectable by microscopy. To check plasmid integration into parasites, DNA was extracted from bulk culture with the QIAamp DNA Mini Kit (Qiagen) and was PCR amplified using primers p16 (5'-GCTAATAAGTAATATCAATATAAGGG-3') and p17 (5'-GGTATTAAATTTTTACCATTCCCATTAGTATTTTGTATAGG-3'). Sequencing was done by Eurofins with the p16 primer and sequences were analyzed using Geneious v8.1.7. Edited parasites were cloned by limiting dilution and selected after 3 weeks by lactate dehydrogenase assay using Malstat reagent ([@bib24]; [@bib1]). Selected clones were *pfk13* genotyped.

*In vitro* drug sensitivity assays (ring-stage survival assay) {#s4-5}
--------------------------------------------------------------

Parental and *pfk13*-edited parasites were phenotyped using the Ring-stage Survival Assay (RSA~0-3h~) method as previously described ([@bib57]). RSA~0-3h~ were performed independently three times for each line. The *pfk13* I543T-mutant IPC4912 strain (MRA1241) was used as an artemisinin-resistant control. RSA~0-3h~ was interpretable if the initial parasitemia was greater than 0.25% and if the growth rate was greater than two-fold per 48 hr. Statistical significance between survival rates of the different lines were calculated using Student's t-test.

Competitive growth fitness assays {#s4-6}
---------------------------------

Fitness assays were performed by inoculating an equal number of wild-type and mutant isogenic ring-stage parasites in a 6 ml culture at an initial parasitemia of 1%. Each co-culture experiment was performed in duplicate on two independent occasions and monitored for 60 days. Saponin-lysed parasite pellets of each co-culture were harvested every two days during 60 days and genomic DNA was extracted using the QIAmp DNA mini kit. The percentage of wild-type or mutant allele in each co-culture was determined using genomic DNA in a TaqMan Allelic Discrimination Real-Time PCR Assays. Wilcoxon signed-rank test was applied to test for statistical significance in the observed percentage of the *pfk13* mutant allele in each of the individual paired co-cultures against an expected no change in the percentage of the mutant.

TaqMan allelic discrimination real-time PCR (qPCR) assays {#s4-7}
---------------------------------------------------------

Primers (forward and reverse) and TaqMan fluorescence-labeled MGB probes (Eurofins, Germany) for real-time quantitative PCR (qPCR) were designed to specifically detect the *pfk13* propeller mutations R539T and C580Y, or the ZFN silent binding mutations, in parasites. The sequences of the forward and reverse primers, and probes (FAM and HEX probe) are shown in [Supplementary file 4](#supp4){ref-type="supplementary-material"}. We first determined the efficiency and sensitivity of amplifying the *pfk13* allele in real-time PCR assays using standard curves comprising 10-fold serially diluted DNA templates ranging from 10 ng to 0.001 ng. Robustness was demonstrated by high efficiency (88--95%) and R^2^ values (0.98--1.00) ([Figure 5---figure supplement 1a and b](#fig5s1){ref-type="fig"}, [Figure 5---figure supplement 1---source data 1](#fig5s1sdata1){ref-type="supplementary-material"}). Next, we tested the quantitative accuracy in genotype calling by performing multiplex qPCR assays using a pre-defined set of mixtures containing plasmids expressing wild-type to mutant alleles in fixed ratios (0:100, 20:80, 40:60, 50:50, 60:40, 80:20, 100:0). The triplicate points clustered tightly, indicating high reproducibility in the data across the fitted curve (linear polynomial order = 2, R^2^ = 0.92 to 0.94) ([Figure 5---figure supplement 1c and d](#fig5s1){ref-type="fig"}, [Figure 5---figure supplement 1---source data 1](#fig5s1sdata1){ref-type="supplementary-material"}). Hence, our assay was able to accurately quantify the different proportions of the mutant alleles in these pre-mixed samples. For a single set of samples, we ran the qPCR on two separate occasions to test the consistency of amplification between runs. The results showed excellent correlations ([Figure 5---figure supplement 2a](#fig5s2){ref-type="fig"}, [Figure 5---figure supplement 2---source data 1](#fig5s2sdata1){ref-type="supplementary-material"}), and thus we concluded that it was not necessary to perform qPCR in replicate runs for each sample. Nevertheless, we always included three replicate qPCR reactions per sample in every run. The data showed consistently high correlations between independent sampling experiments ([Figure 5---figure supplement 2b](#fig5s2){ref-type="fig"},[Figure 5---figure supplement 2---source data 1](#fig5s2sdata1){ref-type="supplementary-material"}).

Purified DNA templates were amplified with a species-specific primer set and the corresponding probe. Briefly, the qPCR reactions for every sample were run in triplicates consisting of 1x QuantiFAST reaction mix containing ROX reference dye (Qiagen, Germany), 0.66 µM of forward and reverse primers, 0.16 µM each of the FAM-MGB and HEX-MGB TaqMan probes, and 10 ng of genomic DNA. Amplification and detection of fluorescence was carried out on the QuantStudio 3 (Applied Biosystems, USA) using the genotyping assay mode with the following cycling conditions: 30 s at 60°C, 5 min at 95°C to activate the enzyme, and 40 cycles of 30 s at 95°C, 30 s at 60°C, and 30 s at 60°C and post-read out at 60°C for 30 s. The final optimized assays always included a positive control of plasmid expressing the mutant or wild-type allele in every PCR reaction to ensure the reaction was successful and a no template control of water as a negative control.

The software analyzed the background fluorescence level and calculated background normalized media dye fluorescence (ΔRn) as a function of cycle number for the wild-type or mutant allele. To determine the wild-type or mutant allele frequency in each sample, we first confirmed the presence of the allele by only taking values where the C~t~ of sample was less than that of the no template control minus three cycles. Next, we subtracted the sample's ΔRn from the background (control plasmid: absence of wild-type or mutant expressing allele) and normalized to 100% (control plasmid: 100% wild-type or mutant expressing allele) to obtain the percentage of mutant and wild-type allele. Then we calculated the average of (mutant and 100% - wild-type) to derive the percentage of mutant allele.

Whole-genome sequencing and variant calling {#s4-8}
-------------------------------------------

For the Guyana samples, we performed selective whole-genome amplification (SWGA) on DNA samples as previously described ([@bib41]) to enrich parasite DNA prior to sequencing on an Illumina HiSeqX instrument at the Broad Institute. We used the enriched DNA to construct Illumina sequencing libraries from the amplified material using the Nextera XT library kit (catalog no. FC-131--1002). We aligned reads to the *P. falciparum* v3 reference genome assembly using BWA-MEM ([@bib31]) and called SNPs and INDELs using the GATK HaplotypeCaller ([@bib55]; [@bib33]; [@bib15]) according to the best practices for *P. falciparum* as determined by the Pf3K consortium (<https://www.malariagen.net/projects/pf3k>). Analyses were limited to the callable segments of the genome ([@bib36]) and excluded sites where over 20% of samples were heterozygous. Additional BAM files for comparative analyses among populations were downloaded from the Pf3k project (release 5; [www.malariagen.net/projects/pf3k](http://www.malariagen.net/projects/pf3k)). For each of four countries in Africa (Democratic Republic of Congo, Ghana, Guinea, and Malawi) and two countries in Southeast Asia (Cambodia and Thailand), 50 samples were chosen based on their high coverage (greatest number of sites with at least 10 × coverage).

Genomic analysis {#s4-9}
----------------

We calculated pairwise identity by descent (IBD) using a hidden Markov model (hmmIBD) ([@bib50]). Samples with a missing call rate \>0.7 were excluded from the analysis. We conducted PCA analyses using R ([@bib44]) after removing samples that showed high relatedness (IBD \>0.5) to another sample with higher sequencing coverage. Pairwise nucleotide diversity was calculated using a custom Perl script (Source Code File 1, Source Code File 2, Source Code File 3). All genomic analyses were limited to samples containing only a single clonal lineage, as determined by THE REAL McCOIL ([@bib11]) or as identified by the Pf3K consortium ([@bib65]).
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This molecular epidemiological study describes a set of *Plasmodium falciparum* samples collected in Guyana that contain the K13 propeller domain mutation most commonly associated with artemisinin resistance in Southeast Asia. The authors show conclusively that mutations associated with artemisinin resistance identified in Guyana are indeed local and belong to a single lineage. They then proceed with an in vitro characterization of parasites from a proximal geographic location (French Guiana) and use those findings to infer the clinical profile of the mutant parasites. This constitutes an important study documenting potential evolution of artemisinin resistance in another continent under the extensive use of artemisinin combined therapy.

**Decision letter after peer review:**

Thank you for submitting your article \"A local emergence and unusual evolution of artemisinin resistance of *Plasmodium falciparum* in eastern Amazonia\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Neil Ferguson as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Liwang Cui (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript describes a set of *P. falciparum* samples collected in Guyana that contain the K13 propeller domain mutation most commonly associated with artemisinin resistance in SE Asia. Genetic evaluation showed that Guyanese parasites with the K13 mutation were closely related to each other, but not to SE Asian resistant clones. The mutation was shown to mediate resistance (delayed clearance in culture) when introduced into parasites with a related genetic background (from French Guiana) and to be associated with slightly decreased fitness in an in vitro assay. While we think that this is a well-written, and valuable report, we have some concerns about the way the results are interpreted and the conclusions derived from them.

Essential revisions:

Two key limitations of the paper are the lack of parasites from Guyana and the lack of clinical data. The authors make good efforts to work around these limitations, but nevertheless they affect the relevance of the findings. Authors should considerably reassess the impact of their conclusions. In particular:

1\) In vitro fitness costs do not necessarily correlate with in vivo success of the mutations. As stated by the authors, in vitro fitness analysis of *kelch13* mutations have historically shown a strong dependency on the background even within the same country (Cambodia) and, given the caveat above, I\'m not sure how to interpret them here. However, competition assays seem to consistently show a higher fitness cost for C580Y mutations compared to others. Interestingly, that\'s the exact opposite of that has been observed in the field, with parasites carrying the C580Y variant rapidly spreading and the R539T slowly disappearing. This is also somehow implied in this work by the fact that C580Y mutations are still circulating after many years.

According to WHO\'s guidelines (e.g. https://apps.who.int/iris/bitstream/handle/10665/274362/WHO-CDS-GMP-2018.18-eng.pdf?sequence=1&isAllowed=y), C580Y is one of the markers recognised for molecular surveillance. However, by the same guidelines, TESs are still the recommended tool for to confirm artemisinin resistance, which according to the authors, have found no evidence of delayed clearance in the country so far. The authors should reassess the impact of the conclusions and word the paper more cautiously (even the title) avoiding any inference about the clinical impact of these data (Discussion paragraph five).

2\) It has already been shown that C580Y causes increases in RSA values. We understand the idea of testing this hypothesis on another background (with the caveats above), but, again, it has been amply demonstrated that there is no "in vitro" effect of the background. In fact, even 3D7+C80Y, despite having no *crt* mutations whatsoever, has been shown to have elevated RSA values. It would be good to clarify what the key message of these experiments is. Also, it is unclear why the authors also decided to test R539T, given that the variant appears to be disappearing. Why not Y493H, which on the other end is becoming more frequent?

3\) The authors decide to edit parasites from a different geographical location. While we understand that this might be due to unstated practical constraints (e.g. the original isolates from Guyana not being available), I believe any conclusion should be taken with a pinch of salt and without any inferential jump. For example, the authors use PCA to infer that parasites from Guyana and French Guiana are genetically similar, but I\'m not sure how they quantified that statement. PCA is influenced by many factors, including, but not limited to, genetic similarity. I think it\'s important to see genetic similarity measured directly and perhaps use publicly available samples to put that measure into context: are those parasites as similar as two parasites from Guyana, from Asia, or from Africa?

4\) Related to the points above, it would be helpful for the authors to include a paragraph addressing limitations in their description. First, clinical delayed clearance after treatment with artemisinins has not been described in Guyana. Second, the number of mutant parasites studied was fairly small, and whole genome sequencing led to some incomplete results. Third, gene editing to link genotypes with phenotypes did not utilize parasites from Guyana, although they were appropriately from a nearby region.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Local emergence in Amazonia of *Plasmodium falciparum k13* C580Y mutants associated with in vitro artemisinin resistance\" for further consideration by *eLife*. Your revised article has been evaluated by Neil Ferguson as SeniorEditor.

Please could you modify the Discussion a little more to take into account the concerns of reviewer 2 below, at least to some extent, then resubmit. Further review will not then be needed.

Reviewer \#1:

The authors have responded appropriately to review requests.

Reviewer \#2:

I\'d like to thank the authors for the all the changes and additional analysis. As a result I believe they\'ve really added solidity to the work and made the presentation more compelling.

I feel satisfied that all points raised were addressed to satisfaction, apart from the request to reword their conclusions more cautiously. I still struggle, in fact, with the over-interpretation of the results and their public health implications. I do believe that these results should be urgently shared with the community but I also believe that WHO\'s guidelines are in place exactly to avoid misinterpretations and to provide an objective depiction of the situation.

More specifically:

Discussion: \"In light of these findings, according to WHO definitions, Guyana has the status of suspected resistance to artemisinin derivatives.\"

I think this statement is at very least misleading, perhaps incorrect. WHO guidelines, in the official policy cited, state that \"Suspected endemic artemisinin resistance is defined as: (among other criteria) ≥ 5% of patients carrying K13 resistance-confirmed mutations (listed in Table 1 (NB: which includes C580Y))\". The authors found in their data a C580Y prevalence of 1.6% (which they themselves define as \"low\") which (luckily!) doesn\'t meet the criteria. It is true that in Region 1 (and in Region 1 only) the prevalence goes over 5% and reaches 8.8% but that result can\'t be generalised to the whole country. (On a side note, it\'s interesting that Region 1 is on the border with Venezuela, where there has been a recent outbreak of cases). I accept that there may be data specific to support that statement but that should be clearly stated and can\'t be attributed to the findings in this study.

Discussion: \"The clinical impact of the *pfk13* C580Y mutation on the therapeutic efficacy of artemisinin-based combination therapies and more precisely artemether/lumefantrine, the first line in Guyana, should be evaluated to test for delayed clearance.\"

It might be semantic but I think there is an important subtlety here. I don\'t think anyone would argue with the amply demonstrated clinical impact of *pfk13* C580Y mutations per se. The question is on the impact of the mutations observed in Guyana on the clinical phenotype. I think the authors should be rephrase their statement more directly, e.g. along the lines of \"The clinical and public health significance of the presence of these mutations on the therapeutic efficacy of artemisinin-based combination therapies in Guyana, and more precisely artemether/lumefantrine -- first line in the country, should be directly evaluated.\"

The reality is that the data presented are very interesting and sufficient to at very least raise an alarm but not to derive any definitive conclusion about the spread of artemisinin resistance. It goes without saying that the situation needs to be monitored very closely and this work offers a fantastic baseline for the future.

Reviewer \#3:

All previous concerns and comments have been properly addressed.
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Author response

> Essential revisions:
>
> Two key limitations of the paper are the lack of parasites from Guyana and the lack of clinical data. The authors make good efforts to work around these limitations, but nevertheless they affect the relevance of the findings. Authors should considerably reassess the impact of their conclusions. In particular:
>
> 1\) In vitro fitness costs do not necessarily correlate with in vivo success of the mutations. As stated by the authors, in vitro fitness analysis of kelch13 mutations have historically shown a strong dependency on the background even within the same country (Cambodia) and, given the caveat above, I\'m not sure how to interpret them here. However, competition assays seem to consistently show a higher fitness cost for C580Y mutations compared to others. Interestingly, that\'s the exact opposite of that has been observed in the field, with parasites carrying the C580Y variant rapidly spreading and the R539T slowly disappearing. This is also somehow implied in this work by the fact that C580Y mutations are still circulating after many years.
>
> According to WHO\'s guidelines (e.g. https://apps.who.int/iris/bitstream/handle/10665/274362/WHO-CDS-GMP-2018.18-eng.pdf?sequence=1&isAllowed=y), C580Y is one of the markers recognised for molecular surveillance. However, by the same guidelines, TESs are still the recommended tool for to confirm artemisinin resistance, which according to the authors, have found no evidence of delayed clearance in the country so far. The authors should reassess the impact of the conclusions and word the paper more cautiously (even the title) avoiding any inference about the clinical impact of these data (Discussion paragraph five).

Thank you for these suggestions. We have carefully reworded the manuscript to clarify these points. The Title has been changed to "Local emergence in Amazonia of *Plasmodium falciparum k13* C580Y mutants associated with in vitro artemisinin resistance."

In the Introduction, we have introduced the concept of partial resistance to artemisinins as defined by the WHO.

Introduction: "Resistance to artemisinin is partial and affects only rings (World Health Organization, 2018). Clinically, this partial resistance trait manifests as a parasite clearance half-life that exceeds 5.5 hours (WWARN K13 Genotype-Phenotype Study Group, 2019). This half-life represents the time required to achieve a two-fold reduction of the parasite biomass. Partial resistance also manifests as persistent parasitemia on day three with a complete clearance of parasites following full treatment with an artesunate monotherapy lasting seven days or with an ACT (World Health Organization, 2018)."

The Discussion also emphasizes that the clinical impact should be assessed, as we do not know the impact of this mutation on the clinical efficacy of artesunate or ACTs: "Further studies will be needed to screen for potential secondary mutations that may be offsetting these fitness costs. It will also be important to examine factors that could drive the persistence of mutant *pfk13* in Guyana despite the apparent fitness cost, including a consideration of local antimalarial drug usage and quality, transmission levels, and population movement."

Discussion: "In light of these findings,according to WHO definitions, Guyana has the status of suspected resistance to artemisinin derivatives (World Health Organization, 2017). The clinical impact of the *pfk13* C580Y mutation on the therapeutic efficacy of artemisinin-based combination therapies and more precisely artemether/lumefantrine, the first line in Guyana, should be evaluated to test for delayed clearance."

> "In vitro fitness costs do not necessarily correlate with in vivo success of the mutations."

We absolutely agree. Our study evaluated the capacity of the mutant to compete with wild-type parasites in culture. This is an artificial evaluation of the fitness cost, in the absence of drug or other parameters important in the in vivo context (including gametocyte production, impacts on transmission, immunity). We recognize that our in vitro findings are therefore only one component of the overall fitness of the parasite.

Using this parameter, our study and previous data reported an impact of the C580Y mutation on parasite growth in vitro, when competing with wild-type isogenic parasites, that clearly depends on the genetic background. In our study, C580Y had a detectable fitness cost in both the O141-A and R086 strains. By comparison, earlier fitness studies showed that the C580Y mutation had a negligible impact on fitness in strains recently culture adapted from Cambodia, contrasting with a substantial fitness cost in the V1/S strain that was adapted to culture decades ago (Straimer et al., 2017). In a separate study, the C580Y mutation had a fitness cost when introduced into an artemisinin-sensitive Thai strain (Nair et al., 2018).

These points are addressed in the manuscript Discussion section, as follows: "These growth rate differences provide a surrogate marker of fitness and do not necessarily predict in vivo success of the mutations, as multiple other parameters are also important including gametocyte production, impacts on transmission, and immunity. Our data show that the C580Y mutation was associated with a more severe growth defect compared to the R539T mutation in these asexual blood stage parasites. A similar finding was also recently reported in C580Y-edited isolates from the Thailand-Myanmar border (Nair et al., 2018), although disparate results were obtained for C580Y-edited isolates from Cambodia (Straimer et al., 2017). These contrasting data underline the influence of the parasite's genomic background, which potentially involves compensatory mutations that impact the overall growth."

In SEA, C580Y parasites are spreading despite the fitness cost observed in some strains, presumably in part because of substantial selection pressure applied to the infected patient population. In many areas of the Greater Mekong Sub-region in SEA, *pfk13* C580Y mutants also often carry additional mutations (outside of the *pfk13* locus) that allow them to resist to the partner drug, piperaquine. This is a very important driver to expand the population of mutant parasites despite the *K13* fitness impact. The situation in Guyana is different as artemether/lumefantrine is the major ACT and no resistance to lumefantrine has been described.

Please refer to the Discussion section of the manuscript, as follows: "In the Guiana Shield, lumefantrine remains a highly effective partner drug for artemisinin, and no mutations or phenotypes associated with lumefantrine resistance have been observed (Legrand et al., 2012). High efficacy of the partner drug could therefore be an important factor limiting the spread of *pfk13* C580Y in Guyana."

To better understand why *pfk13* mutant parasites are still circulating in the region after several years in spite of the apparent fitness cost of the mutation, more investigation is needed to identify the factors that drive persistence. These factors could include antimalarial drug usage, genetic background specific to this country, population movement, and the level of transmission.

Our revised Discussion addresses this as follows: "However, the situation in this part of the world is slightly different from Southeast Asia. First, efforts to monitor *pfk13* mutations in Guyana were not systematically conducted between 2010 and 2017. Sample size could therefore explain why the C580Y mutation was only sporadically observed. Nonetheless, the present study indicates that the mutation has not drastically increased in the parasite population."

"Further studies will be needed to screen for potential secondary mutations that may be offsetting these fitness costs. It will also be important to examine factors that could drive the persistence of mutant *pfk13* in Guyana despite the apparent fitness cost, including a consideration of local antimalarial drug usage and quality, transmission levels, and population movement."

> 2\) It has already been shown that C580Y causes increases in RSA values. We understand the idea of testing this hypothesis on another background (with the caveats above), but, again, it has been amply demonstrated that there is no "in vitro" effect of the background.

The effect of the parasite genetic background on in vitro sensitivity to artemisinins was demonstrated by Straimer et al., 2015, who showed that the C580Y mutation conferred a RSA survival rate that ranged from 1.9% to 24.1% when introduced into five separate strains. This effect was even more important when the strains were genetically very different (e.g. FCB versus Cam3.II). To limit this caveat, we have chosen to genetically modify the only available strains from the same region, namely two strains adapted from French Guiana. To strengthen these results, as suggested by the reviewers, we have improved the demonstration of similarities between French Guianan and Guyanese strains (please refer to our reply to point 3 below).

> In fact, even 3D7+C80Y, despite having no crt mutations whatsoever, has been shown to have elevated RSA values. It would be good to clarify what the key message of these experiments is. Also, it is unclear why the authors also decided to test R539T, given that the variant appears to be disappearing. Why not Y493H, which on the other end is becoming more frequent?

The key message of this experiment was to evaluate the impact of *pfk13* mutations on the in vitro phenotype to artemisinin. We chose to introduce two mutations by gene editing: C580Y because of its presence in Guyana and its prevalence in Southeast Asia and R539T as a positive control of in vitro resistance (as it produced a higher RSA survival phenotype than C580Y across multiple Southeast Asian strains (Ariey et al., 2014, Straimer et al., 2015). Our 2016 report on *pfk13* mutations in SEA (Menard et al., 2016) showed a similar prevalence of R539T and Y493H, with the latter conferring less resistance in gene-edited parasites (e.g. in *pfk13* edited Dd2 parasite clones we observed RSA values of 1.7% for Y493H and 19.4% for R539T; Straimer et al., 2015). We have also examined the *pfk13* data in the WWARN molecular surveyor database. Of 1992 genomes analyzed we observed 62 with R539T and 39 with Y493H. Of the 394 genomes reported for the period 2015-2017 (primarily from the first two years), we note that 6 had R539T (from 2015 and 2016) and 3 had Y493H (all from 2015). Thus, we do not see clear evidence in the literature or the WWARN database analysis that Y493H is expanding. There may be data specific to a certain region that has not been published and therefore could not inform our selection of mutations. Our results also demonstrated that the in vitro impact of these two mutations was similar to the one observed on Cambodian strains, i.e. we observed a higher cost of the R539T mutation along with high survival rates.

These details have been added to the Discussion: "The slower trajectory of *pfk13* C580Y may also be due to an impaired asexual blood-stage growth rate, and the absence of compensatory mutations, which have been hypothesized to aid the spread of the C580Y mutation in Southeast Asia (Amato et al., 2018, Li et al., 2019). We chose to introduce two *pfk13* mutations by gene editing: C580Y mutation because of its presence in Guyana and its dominance in Southeast Asia, and R539T as a positive control for in vitroresistance, as it exhibits the highest RSA observed in Southeast Asian strains along with I543T (Ariey et al., 2013, Straimer et al., 2015)."

> 3\) The authors decide to edit parasites from a different geographical location. While we understand that this might be due to unstated practical constraints (e.g. the original isolates from Guyana not being available), I believe any conclusion should be taken with a pinch of salt and without any inferential jump. For example, the authors use PCA to infer that parasites from Guyana and French Guiana are genetically similar, but I\'m not sure how they quantified that statement. PCA is influenced by many factors, including, but not limited to, genetic similarity. I think it\'s important to see genetic similarity measured directly and perhaps use publicly available samples to put that measure into context: are those parasites as similar as two parasites from Guyana, from Asia, or from Africa?

This is a very valid point, thank you for bringing it to our attention. We have included a new supplemental figure (Figure 2---figure supplement 1) that depicts the absolute rate of SNP differences between isolates from the samples utilized in the PCA. This new figure shows that while pairwise comparisons of parasites reveals moderately higher divergence between French Guiana and Guyana than within Guyana (indicating slight genetic divergence between the populations), there is greater genetic similarity between parasites from Guyana and French Guiana than is typically observed for pairs of parasites from the same country in other parts of the world, notably Cambodia, Thailand, Ghana, Malawi, the Democratic Republic of Congo, and Guinea. We thank the reviewer for helping us to clarify this important point.

> 4\) Related to the points above, it would be helpful for the authors to include a paragraph addressing limitations in their description. First, clinical delayed clearance after treatment with artemisinins has not been described in Guyana. Second, the number of mutant parasites studied was fairly small, and whole genome sequencing led to some incomplete results. Third, gene editing to link genotypes with phenotypes did not utilize parasites from Guyana, although they were appropriately from a nearby region.

Our revised Discussion now states, the two major limitations of our study (namely the small number of genotyped parasites and the construction of isogenic lines in French Guianan but not Guyanese strains). Other limitations have also been stated in other paragraphs of the Discussion. Regarding the absence of delayed parasite clearance times in Guyana, we note that a therapeutic efficacy study has been conducted only once in this region. However, the sample size was low and did not include a C580Y carrier. The impact of the *pfk13* C580Y mutation on therapeutic response to confirm the status of the country still needs to be assessed. This task will be difficult as the mutation is rare and therefore the probability to observe a C580Y infection among included patients is very low.

Discussion: "The clinical impact of the *pfk13* C580Y mutation on the therapeutic efficacy of artemisininbased combination therapies and more precisely artemether/lumefantrine, the first line in Guyana, should be evaluated to test for delayed clearance. We note that our study had limitations including the small number of analyzed samples and the in vitrophenotypic impact evaluated in parasites from nearby French Guiana and not Guyana itself. Nonetheless, we observed that *pfk13* mutants still circulated in 2016-2017. Given their decreased susceptibility to DHA in vitro, these mutants are likely to expose the partner drug to the risk of emerging resistance."

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> Please could you modify the Discussion a little more to take into account the concerns of reviewer 2 below, at least to some extent, then resubmit. Further review will not then be needed.
>
> Reviewer \#2:
>
> I\'d like to thank the authors for the all the changes and additional analysis. As a result I believe they\'ve really added solidity to the work and made the presentation more compelling.
>
> I feel satisfied that all points raised were addressed to satisfaction, apart from the request to reword their conclusions more cautiously. I still struggle, in fact, with the over-interpretation of the results and their public health implications. I do believe that these results should be urgently shared with the community but I also believe that WHO\'s guidelines are in place exactly to avoid misinterpretations and to provide an objective depiction of the situation.
>
> More specifically:
>
> Discussion: \"In light of these findings, according to WHO definitions, Guyana has the status of suspected resistance to artemisinin derivatives.\"
>
> I think this statement is at very least misleading, perhaps incorrect. WHO guidelines, in the official policy cited, state that \"Suspected endemic artemisinin resistance is defined as: (among other criteria) ≥ 5% of patients carrying K13 resistance-confirmed mutations (listed in Table 1 (NB: which includes C580Y))\". The authors found in their data a C580Y prevalence of 1.6% (which they themselves define as \"low\") which (luckily!) doesn\'t meet the criteria. It is true that in Region 1 (and in Region 1 only) the prevalence goes over 5% and reaches 8.8% but that result can\'t be generalised to the whole country. (On a side note, it\'s interesting that Region 1 is on the border with Venezuela, where there has been a recent outbreak of cases). I accept that there may be data specific to support that statement but that should be clearly stated and can\'t be attributed to the findings in this study.

The threshold of 5% of *pfk13* mutants defined by WHO to classify countries regarding artemisinin resistance has been met on several occasions in Guyana, first in 2010, then in 2016-2017 where in Region 1 the threshold has been punctually overreached. This classification is at the country scale even if in 2016-2017 only Region 1 met the threshold. In 2010, the proportion was reached on a sample set of 98 samples collected in different region of the country. Mutants were observed in Region 1 and 7, mainly in Region 7. The situation is evolving and a marker could disappear or even increase for reasons that are currently unclear but in light of these findings and criteria, six years apart, we could not avoid to mention that Guyana has the status of suspected resistance to artemisinin derivatives.

Discussion: "WHO has categorized countries regarding artemisinin resistance based on *pfk13* mutant prevalence and the clinical response to artemisinin derivatives (World Health Organization, 2017). The threshold of 5% of *pfk13* mutants has been met on several occasions in Guyana, first in 2010 (Chenet et al., 2016), then punctually in 2016-2017 in Region 1. The situation is evolving and a marker could disappear for reasons that are currently unclear. Nonetheless, in light of these findings, Guyana has the status of suspected resistance to artemisinin derivatives (World Health Organization, 2017)."

> Discussion: \"The clinical impact of the pfk13 C580Y mutation on the therapeutic efficacy of artemisinin-based combination therapies and more precisely artemether/lumefantrine, the first line in Guyana, should be evaluated to test for delayed clearance.\"
>
> It might be semantic but I think there is an important subtlety here. I don\'t think anyone would argue with the amply demonstrated clinical impact of pfk13 C580Y mutations per se. The question is on the impact of the mutations observed in Guyana on the clinical phenotype. I think the authors should be rephrase their statement more directly, e.g. along the lines of \"The clinical and public health significance of the presence of these mutations on the therapeutic efficacy of artemisinin-based combination therapies in Guyana, and more precisely artemether/lumefantrine -- first line in the country, should be directly evaluated.\"

We thank the reviewer for this suggestion. The sentence has been added to replace the previous one as follows: "The clinical and public health significance of the presence of these mutations on the therapeutic efficacy of artemisinin-based combination therapies in Guyana, and more precisely artemether/lumefantrine -- first line in the country, should be directly evaluated."

[^1]: These authors contributed equally to this work.

[^2]: These authors also contributed equally to this work.
